To continue to advance our drug development process, we will refine our relevant in vitro and in vivo data. 

Upon receiving TGA approval, we will begin our first human clinical trial. Once our safety profile has been established, we will move into Phase II and Phase III trials to determine the efficacy of our drug in patients with psoriasis. 

Concurrently, we will also begin development work on another formulation: a topical cream. 

We are excited to be shaping the future of psoriasis treatment. 

Our journey in pioneering innovative treatments for psoriasis is far from over. With each step forward, we are committed to making a significant impact on the lives of those affected by this condition. Stay tuned as our story continues to unfold.

Thank you for joining us on this journey.